Anti-rheumatoid drugs Flashcards
Describe pathophysiology of RA
Either decrease of anti inflammatory or increase in pro inflammatory molecules
Leading to dissolution of articular cartilage and bone. Formation of a pannus (inflammatory cell infiltrate into synovium so fibrovascular layer over joint surface)
Clinical features of RA
Early morning stiffness (>1 hour)
Symmetrical pain and swelling of small joints (at least 3)
Rheumatoid nodules
Hand deformities
Immunosuppressants used to treat autoimmune disorders
Corticosteroids
Calcineurin inhibitors (tacrolimus and ciclosporin)
Azathioprine
Mycophenolate mofetil
Examples of DMARDs
Methotrexate Sulphasalazine Anti-TNF Rituximab Cyclophosphamide
MoA of corticosteroids
Inhibit T cell activation
Inhibit IL1 and IL6 (proinflammatory)
Indications for azothioprine
SLE
IBD
Vasculitis
What needs to be done prior to starting azathioprine
Test TPMT activity (metabolises azathioprine)
If lower activity need lower dose
MoA of azathioprine
Steroid sparing drug
Cleaved to 6-MP which decreases DNA synthesis
Side effects of azathioprine and what needs to be monitored
Bone marrow suppression - need to monitor FBC
Malignancy and infection risk
Hepatitis - need to monitor LFTs
Indications for calcineurin inhibitors
Transplant
Atopic dermatitis
Psoriasis
MoA of calcineurin inhibitors
Ciclosporin binds to cyclophilin
Tacrolimus binds to tacrolimus binding protein
Complexes bind to calcineurin which prevents calcineurin from activating T cell to start IL2 transcription
Sided effects of calcineurin inhibitors and what needs monitoring
Nephrotoxic - monitor GFR and BP
Diarrhoea and vomiting
Hyperlipidaemia - monitor cholesterol
Indications for MM
Transplant
Lupus nephritis
MoA of MM
MPA (prodrug) inhibits inosine monophosphate dehydrogenase so prevents guanine synthesis
This impairs B and T cell proliferation
Indications for methotrexate
RA
Malignancy
Psoriasis
Crohn’s